Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

Laura Ferrero-Miliani; Ditte Bjerre; Claus Stage; Majbritt Busk Madsen; Gesche Jűrgens; Kim Peder Dalhoff; Henrik Berg Rasmussen

doi:10.2217/pgs-2017-0052

Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

Laura Ferrero-Miliani, Ditte Bjerre, Claus Stage, Majbritt Busk Madsen, Gesche Jűrgens, Kim Peder Dalhoff, Henrik Berg Rasmussen

Institut for Klinisk Medicin

2 Citationer (Scopus)

Abstract

The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1. Several of these SNVs were novel. The frequencies of SNVs with a potential functional impact were below 0.02 suggesting limited pharmacogenetic potential for CES1 genotyping. In silico PCR revealed that the majority of the primer pairs for amplification of CES1 or CES1A2 in three previous studies lacked specificity, which partially explains a limited overlap with our findings.

Originalsprog	Engelsk
Tidsskrift	Pharmacogenomics
Vol/bind	18
Udgave nummer	13
Sider (fra-til)	1241-1257
Antal sider	17
ISSN	1462-2416
DOI	https://doi.org/10.2217/pgs-2017-0052
Status	Udgivet - aug. 2017

Adgang til dokumentet

10.2217/pgs-2017-0052

Citationsformater

@article{c5a4ccbd0f654e1da2e1e3f8cc6bc70f,

title = "Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1",

abstract = "The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1. Several of these SNVs were novel. The frequencies of SNVs with a potential functional impact were below 0.02 suggesting limited pharmacogenetic potential for CES1 genotyping. In silico PCR revealed that the majority of the primer pairs for amplification of CES1 or CES1A2 in three previous studies lacked specificity, which partially explains a limited overlap with our findings.",

author = "Laura Ferrero-Miliani and Ditte Bjerre and Claus Stage and Madsen, {Majbritt Busk} and Gesche J{\H u}rgens and Dalhoff, {Kim Peder} and Rasmussen, {Henrik Berg}",

year = "2017",

month = aug,

doi = "10.2217/pgs-2017-0052",

language = "English",

volume = "18",

pages = "1241--1257",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "13",

}

TY - JOUR

T1 - Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

AU - Ferrero-Miliani, Laura

AU - Bjerre, Ditte

AU - Stage, Claus

AU - Madsen, Majbritt Busk

AU - Jűrgens, Gesche

AU - Dalhoff, Kim Peder

AU - Rasmussen, Henrik Berg

PY - 2017/8

Y1 - 2017/8

N2 - The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1. Several of these SNVs were novel. The frequencies of SNVs with a potential functional impact were below 0.02 suggesting limited pharmacogenetic potential for CES1 genotyping. In silico PCR revealed that the majority of the primer pairs for amplification of CES1 or CES1A2 in three previous studies lacked specificity, which partially explains a limited overlap with our findings.

AB - The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1. Several of these SNVs were novel. The frequencies of SNVs with a potential functional impact were below 0.02 suggesting limited pharmacogenetic potential for CES1 genotyping. In silico PCR revealed that the majority of the primer pairs for amplification of CES1 or CES1A2 in three previous studies lacked specificity, which partially explains a limited overlap with our findings.

U2 - 10.2217/pgs-2017-0052

DO - 10.2217/pgs-2017-0052

M3 - Journal article

C2 - 28786738

SN - 1462-2416

VL - 18

SP - 1241

EP - 1257

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 13

ER -

Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater